Australian New Zealand
Clinical Trials Registry
paclitaxel 250 mg/m2 q 2 weeks x 3 followed by
cyclophosphamide 840 mg/m2, methotrexate 57 mg/m2,
fluorouracil 840 mg/m2 (CMF) q 2 weeks x 3. GCSF support
in all cycles.
ET-CMF: Epirubicin 83 mg/m2 + paclitaxel 187 mg/m2 q 3
weeks x 4 followed by cyclophosphamide 840 mg/m2,
methotrexate 57 mg/m2, fluorouracil 840 mg/m2 (CMF) q 2
weeks x 3. GCSF support in all cycles.
Patients with ER/PgR-positive tumors received tamoxifen 20
mg daily for five years. Premenopausal patients received
additional treatment with an LH-RH analog for two years.
Postmenopausal patients received tamoxifen 20 mg daily for
2-3 years followed 2-3 years of daily examestane 25 mg. All
patients who underwent partial mastectomy or with tumors
>5 cm and/or with ≥4 infiltrated axillary nodes, irrespectively
of the type of surgery, were irradiated. Radiation therapy and
hormonal therapy were administered after the completion of
epithelial breast cancer;
pathological stage T1-4 N1-2 M0;
Eastern Cooperative Oncology
Group performance status 0-1;
normal cardiac function; and
adequate bone marrow, hepatic
and renal function.
sequential chemotherapy with
epirubicin, paclitaxel and CMF in
patients with high-risk breast cancer:
safety analysis of the Hellenic
Cooperative Oncology Group
randomized phase III trial HE
10/00. Ann Oncol. 2008;19:853-60.
Gogas H, Dafni U, et al.
sequential versus concomitant
administration of epirubicin and
paclitaxel in patients with node-
positive breast cancer: 5-year
results of the Hellenic Cooperative
Oncology Group HE 10/00 phase
III Trial. Breast Cancer Res Treat.